文献速递免疫规划卫生政策与健康促进

秘鲁免疫规划中三价换四价灭活流感疫苗的成本效果分析

Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
PubMed 文献 · Vaccine · 2021-06-12

该研究采用决策分析静态成本效果模型,从支付方和社会视角评估秘鲁免疫规划由三价流感疫苗(TIV)换成四价流感疫苗(QIV)的成本效果。结果显示换成QIV可额外预防29,126例病例、54例住院和23例死亡,增量成本效果比为每获得一个QALY需16,649美元,QIV具有成本效果的概率为83.8%。

要点

  • 换用QIV可额外预防29,126例流感病例(含12,815例就诊)、54例住院和23例死亡。
  • 支付方视角下可节省505,206美元,部分抵消引入QIV的投资。
  • ICER为每QALY 16,649美元,QIV具成本效果的概率为83.8%(阈值为人均GDP三倍)。

核心结论

  • 在秘鲁免疫规划中以QIV替代TIV预计是具有成本效果的策略,尤其在年幼儿童和老年人中。
  • 若在高危人群中达到卫生部目标覆盖率,QIV的健康收益将更为重要。

研究设计与样本

  • 决策分析静态成本效果模型,适配秘鲁场景,涵盖支付方和社会两种视角。

主要发现

  • 换用QIV可额外预防29,126例流感相关病例(含12,815例就诊)、54例住院和23例死亡,主要发生在<2岁和>60岁人群。
  • 支付方视角下可节省505,206美元,部分抵消引入QIV所需的投资。
  • 增量成本效果比(ICER)为每获得一个QALY需16,649美元。
  • QIV具有成本效果的概率为83.8%(阈值取人均GDP三倍)。
  • 模型结果的主要驱动因素包括疫苗对B型流感病毒的效力、匹配程度、疫苗价格和B型流感归因病例比例。

临床怎么用

  • 在秘鲁免疫规划中可考虑将TIV替换为QIV,以提升对B型流感的防护并改善成本效果。
  • 优先在年幼儿童和老年人等高危人群中推广QIV,并努力达到卫生部目标覆盖率以放大健康收益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seasonal influenza is an acute respiratory infection mostly caused by type A and B influenza viruses. The severe form of the infection can be life-threatening and lead to a significant burden. Vaccination is the most efficient way of preventing influenza infections and limit this burden. OBJECTIVES: To assess the cost-effectiveness of switching from a trivalent influenza vaccine (TIV) to a quadrivalent influenza vaccine (QIV) in the vaccination programme in Peru, and to evaluate the health and economic impact of reaching the vaccination coverage rate targeted by the Ministry of Health. METHODS: A decision-analytic static cost-effectiveness model, was adapted to the Peruvian setting under both payer and societal perspectives. RESULTS: A switch from TIV to QIV would prevent 29,126 additional cases (including 12,815 consultations), 54 hospitalisations, and 23 deaths related to influenza, mostly in the population <2 years-old and >60 years-old. This would lead to a saving of US $505,206 under the payer perspective, that would partially offset the investment necessary to introduce QIV into the immunisation programme. The resulting incremental cost-effectiveness ratio (ICER) is $16,649 per QALYs gained. The main drivers of the model results were vaccine efficacy against influenza B viruses, degree of match, vaccines prices and proportion of cases attributable to influenza B. The robustness of the results seems satisfactory as QIV has the probability of being a cost-effective strategy of 83.8% (considering a threshold of three GDP per capita). Reaching the coverage targeted by the Ministry of Health would result in health benefits and disease management savings, and lower ICERs. CONCLUSION: Introducing QIV instead of TIV in the Peruvian immunisation programme is expected to be a cost-effective strategy, especially in younger children and the elderly. The benefit of QIV would be even more important if the coverage targeted by the Ministry of Health would be reached in the most vulnerable groups.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bellier L, Petitjean A, Sarazu T, et al. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme. Vaccine. 2021. PMID: 34130885. doi:10.1016/j.vaccine.2021.05.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。